Journal Press India^®

Author Details ( * ) denotes Corresponding author

Cryptosporidium parvum is the most common enteric protozoan pathogens affecting humans worldwide. Currently approved drugs to treat cryptosporidiosis are ineffective and no vaccines exist against C. parvum. Here, We docked benzoxazole derivatives collected from literature with Cryptosporidium parvum inosine 5′-monophosphate dehydrogenase using AutoDock4.2 tool, which resulted in energy-based descriptors such as Binding Energy, Intermolecular Energy, Internal Energy, Torsional Energy, vdW + Hbond + desolv Energy and electrostatic energy. Molecular dynamics (MD) simulation studies were performed through the NAMD graphical user interface embedded in visual molecular dynamics. After that, we have built quantitative structure activity relationship (QSAR) model using energy-based descriptors yielding correlation coefficient r2 of 0.7948. To assess the predictive performance of QSAR model, different cross-validation procedures were adopted. Our results suggests that ligand-receptor binding interactions for inosine 5′-monophosphate dehydrogenase employing QSAR modeling seems to be a promising approach to design more potent inosine 5′-monophosphate dehydrogenase inhibitors prior to their synthesis.

Keywords

Cryptosporidium Parvum; Docking; Inosine 5′-monophosphate Dehydrogenase; AutoDock4.2; Benzoxazole Derivatives. QSAR

1. Amadi B, Mwiya M, Sianongo S, Payne L, Watuka A, Katubulushi M and Kelly P. BMC Infect Dis. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. 9, 2009, 195.


2. Amadi, B., Mwiya, M., Musuku, J., Watuka, A., Sianongo, S., Ayoub, A., Kelly, P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360, 2002, 1375–1380.


3. Anonymous UNAIDS report on the global AIDS epidemic 2010. http://www.unaids.org/globalreport/.


4. Asma, I., S. Johari, B.H.L., Sim, and Y.A.L. Lim. (2011). How common is intestinal parasitism in HIV infected patients in Malaysian? Trop Biomed. 28, 2011, 400–410.


5. Assefa, S., B. Erko, G. Medhin, Z. Assefa and T. Shimelis. Intestinal parasitic infections in relation to HIV/AIDS status, diarrhea and CD4 T cell count. BMC Infect Dis. 9, 2009, 155.


6. Baishanbo, A., Gargala, G., Delaunay, A., François, A., Ballet, J.J., Favennec, L. Infectivity of Cryptosporidium hominis and Cryptosporidium parvum genotype 2 isolates in immunosuppressed Mongolian gerbils. Infection & Immunity 73, 2006, 5252–5525.


7. Bhadauria D, Goel A, Kaul A, Sharma RK, Gupta A, Ruhela V, Gupta A, Vardhan H and Prasad N. Transpl Infect Dis. Cryptosporidium infection after renal transplantation in an endemic area. 17(1), 2015, 48-55.


8. Bissue, F, Cotte L, Rabodonirina M, Rougier, P, Piens Rougier, MA, Trepo C. Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clinical Infectious Diseases 18, 1994, 447–449.


9. Blagburn, BL, Drain, KL, Land TM, Kinard RG, Moore PH, Lindsay DS, Patrick DA, Boykin DW, Tidwell RR. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model. Antimicrobial Agents & Chemotherapy 42, 1998, 2877–2882.


10. carey CM, Lee H, Trevors, JT, Biology, persistence anddetection of Cryptosporidium parvum and Cryptosporidium hominis oocyst. Water Res. 38, 2004, 818-862.


11. Casemore, D.P., R.L.Sands and A. Curry. (1985). Cryptosporidium species a ‘‘new’’ human pathogen. J Clin Pathol 38, 1995, 1321–1336.


12. Checkley W, White AC Jr, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, Fayer R, Griffiths JK, Guerrant RL, Hedstrom L, Huston CD, Kotloff KL, Kang G, Mead JR, Miller M, Petri WA Jr, Priest JW, Roos DS, Striepen B, Thompson RC, Ward HD, Van Voorhis WA, Xiao L, Zhu G and Houpt ER. Lancet Infect Dis. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. 15(1), 2014, 85-94.


13. Clezy K, Gold J, Blaze J, Jones P. Paramomycin for the treatment of cryptosporidial diarrhoea in AIDS patients. AIDS 5, 1991, 1146–1147.


14. Corso, P.S., M.H.Kramer, K.A. Blair, D.G. Addiss, J.P.Davis and A.C. Haddix. Cost of illness in the 1993 waterborne Cryptosporidium outbreak, Milwaukee, Wisconsin. Emerg Infect Dis. 9, 2003, 426–431.


15. Dionisio D, Orsi A, Sterrantino G, Meli M, Di Lollo S, Ibba Manneschi L, Trotta, M, Pozzi M, Sani L, Leoncini F. Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. Journal of Clinical Pathology 51, 1998, 138–142.


16. Downey AS, Chong CR, Graczyk TK, Sullivan, DJ. Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrobial Agents & Chemotherapy 52, 2008, 3106–3112.


17. DuPont, HL, CL Chapell CR, Sterling PC, Okhuysen, JB, Rose, W Jakubowski. The infectivity of Cryptosporidium parvum in healthy volunteers. N Engl J Med 332, 1995, 855-859.


18. Ebrahimzade E, Shayan P, Asghari Z, Jafari S and Omidian Z. Iran J Parasitol. Isolation of Small Number of Cryptosporidium parvum Oocyst Using Immunochromatography. 9(4), 2014, 482-90.


19. Fayer R. Cryptosporidium: A water-borne zoonotic parasite. Veterinary Parasitology.126, 2004, 37–56.


20. Fichtenbaum CJ, Ritchie DJ, Powderly WG. Use of paromomycin for treatment of Cryptosporidium in patients with AIDS. Clinical Infectious Diseases 6, 1993, 298–300.


21. Florez AC, DA Gracia, L Moncada, M Beltran. Prevalence of microsporidia and other intestinal parasites with HIV infection. Bogota Biomedica 23, 2003, 274– 282.


22. Gargala, G. (2008). Drug treatment and novel drug target against Cryptosporidium. Parasite. 15(3): 275-81.


23. Gargala G, Delauney A, Li X, Brasseur Ph, Favennec, L, Ballet JJ. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. Journal of Antimicrobial Chemotherapy 46, 2000, 57–60.


24. Giacometti A, Burzacchini F, Cirioni O, Barchiesi M, Scalise G. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. European Journal of Clinical Microbiology & Infectious Diseases 18, 1999, 885–889.


25. Giacometti A, Burzacchini F, Cirioni O, Barchiesi M, Scalise G. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. European Journal of Clinical Microbiology & nfectious Diseases 18, 1999, 885–889.


26. Giacometti A, Cirioni O, Barchiesi F, Ancarani F, Scalise G. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. Journal of Antimicrobial Chemotherapy 45, 2000, 453–456.


27. Griffiths, J.K., Balakrihnan, R., Widmer, G., Tzipori, S. (1998). Paromomycin and genecitin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery. Infection & Immunity 66, 1998, 3874–3883. [28.] Guitard, J., Menotti, J., Desveaux, A., Alimardani, P., Porcher, R., Derouin, F., Kapel, N. Experimental study of the effects of probiotics on Cryptosporidium parvum infection in neonatal rats. Parasitology Research 99, 2006, 522–527.


28. Harp JA. Parasitic infections of the gastrointestinal tract. Curr Opin Gastroenterol. 19, 2003, 31-36.


29. Hommer V, Eichholz J, Petry F. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. Journal of Antimicrobial Chemotherapy 52, 2003, 359–364.


30. Howe AD, S Forster, S Morton, R Marshall, KS, Osborn P. Wright, and P. R. Hunter. Cryptosporidium Oocysts in a Water Supply Associated with a Cryptosporidiosis Outbreak. Emerg Infect Dis. 8(6), 2002, 619–624.


31. Hunter. Cryptosporidium Oocysts in a Water Supply Associated with a Cryptosporidiosis Outbreak. Emerg Infect Dis. 8(6), 2002, 619–624.


32. Iannotti LL, Trehan I, Clitheroe KL and Manary MJ. (2014). J Paediatr Child Health. Diagnosis and treatment of severely malnourished children with diarrhoea.. doi: 10.1111/jpc.12711.


33. Kadappu KK, Nagaraja MV, Rao PV, Shastry, BA, Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. Journal of Postgraduate Medicine 48, 2002, 179–181.


34. Khan, W.A., K.A. Rogers, M.M. Karim, S. Ahmed and P.L.Hibberd, et al. Cryptosporidiosis among Bangladeshi children with diarrhea: a prospective, matched, case-control study of clinical features, epidemiology and systemic antibody responses. Am J Trop Med Hyg. 71, 2004, 412–419.


35. Kjos SA, M Jenkins, PC Okhuysen, CL Chappell. Evaluation of recombinant oocyst protein CP41 for detection of Cryptosporidium-specific antibodies. Clin Diagn Lab Immunol. 12, 2005, 268-272.


36. Lau AH, Lam NP, Piscitelli SC, Wilkes ., Danzinger, LH. Clinical pharmacokinetics of metronidazole and other nitro-imidazole anti-infectives. Clinical pharmacokinetics 23, 1992, 328–364.


37. Lemeteil D, Roussel F, Favennec L, Ballet JJ, Brasseur P. Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model. Journal of Infectious Diseases 167, 1993, 766–769.


38. Lemeteil D, Roussel F, Favennec, L, Ballet JJ, Brasseur P. Assessment of candidate anti cryptosporidial agents in an immune suppressed rat model. Journal of Infectious Diseases 167, 1993, 766–769.


39. Li X, Brasseur P, Agnamey P, Lemeteil D, Favennec L, Ballet JJ, Rossignol JF. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model. Folia Parasitologica 50, 2003, 19–22.


40. Lima AA, GFang, JBSchorling, L de Albuquerque, JF McAuliffe, et al. Persistent diarrhea in northeast Brazil: etiologies and interactions with malnutrition. Acta Paediatr Suppl.381, 1992, 39–44.


41. MakJW. Important zoonotic intestinal protozoan parasites in Asia. Trop Biomed 21, 2004, 39-50.


42. Mele R, Gomez Morales MA, Tosini F, Pozio E. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. International Journal for Parasitology 33, 2003, 757–764.


43. Molbak, K., M.Andersen, P.Aaby, N. Hojlyng and M. Jakobsen, et al. Cryptosporidium infection in infancy as a cause of malnutrition: a community study from Guinea-Bissau, west Africa. Am J Clin Nutr 65, 1997, 149–152.


44. Molbak K, N Hojlyng, A, Gottschau, J, C Sa and L Ingholt, et al. Cryptosporidiosis in infancy and childhood mortality in Guinea Bissau, west Africa. 307, 1993, 417–420.


45. Navin TR, R Weber, DJVugia, D Rimland and JM. Roberts et al. Declining CD4 T Lymphocytes counts are associated with increased risk of enteric parasitosis and chronic diarrhea: results of a 3 year longitudinal study. J Acqu Imm Deff Syndr Hum Retroviril. 20, 1999, 154–159.


46. Ochoa TJ, ESalazar-Lindo, TG Cleary. Management of children with infection-associated persistent diarrhea. Semin Pediatr Infect Dis. 15, 2004, 229-236.


47. Percival, SL, JTWalker, PR Hunter. Microbiological aspects of biofilms and drinking water. Boca Raton (FL): CRC Press. 2000


48. Perec-Matysiak A, Buńkowska-Gawlik K, Zaleśny G, Hildebrand J Ann Agric Environ Med. Small rodents as reservoirs of Cryptosporidium spp. and Giardia spp. in south-western Poland. 22(1), 2015, 1-5.


49. Randhawa, SS, Randhawa, SS, Zahid, UN, Singla, LD, Juyal, PD. Drug combination therapy in control of cryptosporidiosis in Ludhiana district of Punjab. J Parasit Dis. 36(2), 2012, 269-72.


50. Riggs MW, Schaefer, DeborahA, Kapil, SushilaJ, Barley-Maloney, Perryman LE. Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis. Antimicrobial Agents and Chemotherapy 46, 2000, 275–282.




52. Rossignol, JF. Cryptosporidium and Giardia: Treatment options and prospects for new drugs. Experimental Parasitology. 124, 2010, 45–53


53. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebocontrolled study of nitazoxanide. Journal of Infectious Diseases 184, 2001, 103–106.


54. Rossignol JF, Hidalgo H, Feregrino M, Higuera F, Gomez WH, Romero JL, Padierna, J., Geyne, A, Ayers MS. A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in AIDS patients. Transactions of the Royal Society of Tropical Medicine & Hygiene 92, 1998, 663–666.


55. Rossignol, JF, Kabil SM, Younis AM, El-Gohary Y. Double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in 90 immunocompetent adults and adolescents from the Nile delta of Egypt. Clinical Gastroenterology & Hepatology 4, 2006, 320–324.


56. Ryan U, Hijjawi N. Int J Parasitol. New developments in Cryptosporidium research. 7519(15), 2015, 47-58.


57. Sallon S, RJ Deckelbaum, IISchmid, SHarlap, M Baras, et al. Cryptosporidium, malnutrition, and chronic diarrhea in children. Am J Dis Child 142, 1998, 312–315.


58. Smith, HV, RAB Nichols,AM Grimason. Cryptosporidium excystation and invasion: getting to the guts of the matter. Trends Parasitol 21, 2005, 133–142.


59. SnellingWJ, L Xiao G, Ortega- Pierres, CJ, Lowery J E, Moore, JR, Rao S Smyth BC, Millar PJ, Rooney M, Matsuda F, Kenny J Xu J, SG Dooley. Cryptosporidiosis in developing countries. J Infect Developing Countries. 1(3), 2007, 242-256


60. Sponseller JK, Griffiths JK and Tzipori S. (2014). Clin. Microbiol. Rev. The evolution of respiratory Cryptosporidiosis: evidence for transmission by inhalation. 27(3), 2014, 575-86.


61. Tandon N, Gupta S. Indian J Med Paediatr Oncol. Cryptosporidiosis causing severe persistent diarrhea in a patient with multiple myeloma: A Case report and brief review of literature. 35(1), 2014, 93-5.


62. Theodos, C.M., Griffiths, J.K., D’Onfro, J., Fairfield, A., Tzipori, S. The efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrobial Agents & Chemotherapy 42, 1998,1959–1965.


63. Theodos CM, Griffiths JK, D’Onfro J, Fairfield A, Tzipori S. The efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrobial Agents & Chemotherapy 42, 1998, 1959–1965.


64. Uip DE, Lima ALL, Amato VS, Boulo, M, Neto VA, Bem David D. Roxithromycin treatment for diarrhoea caused by Cryptosporidium spp. In patients AIDS. Journal of Antimicrobial Chemotherapy 41 (Suppl. B), 1998, 93–97.


65. UmejiegoNN, Gollapalli D, Sharling, L, Volftsum A, Lu, J, Benjamin, NN, Stroupe, AH, Riera, TV, Striepen, B and Hedstrom, L. (2008). Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis. Chem Biol. 15(1): 70-7.


66. Walllace, MR, Nguyen, MT, Newton, JAJ. Use of paromomycin for the treatment of cryptosporidiosis in patients with AIDS. Clinical Infectious Diseases 17, 1993, 1070–1073.


67. White Jr, AC, Chappell CL, Hayat CS, Kimball, KT, Flanigan TP, Goodgame RW. Paromomycin for cryptosporidiosis in AIDS: a prospective, doubleblind trial. Journal of Infectious Diseases 170, 1994, 419–424.


68. Young I, Smith BA and Fazil AJ. Water Health. A systematic review and meta-analysis of the effects of extreme weather events and other weather-related variables on Cryptosporidium and Giardia in fresh surface waters. 13(1), 2015, 1-17.


69. Zardi EM, Picardi A, Afeltra A. Treatment of cryptosporidiosis in immune compromised hosts. Chemotherapy 51, 2005, 193–196.


70. Zhou R, Feng Y, Chen XM. Parasitology. Non-coding RNAs in epithelial immunity to Cryptosporidium infection. 141(10), 2014, 1233-43.


71. Genomic data information


72. All genomic data will be retrieved from the NCBI complete genome repository.


73. NCBI complete genomes (ftp://ftp.ncbi.nih.gov/genomes/)